New molecular entities/new biologics - Boniva - Ibandronate - Roche/Glaxosmithkline - Treatment and prevention of osteoporosis

被引：0

|

作者：

不详

机构：

来源：

FORMULARY | 2003年 / 38卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：392 / 392

页数：1

相关论文

共 50 条

[31] New molecular entities
不详
FORMULARY, 2005, 40 (08) : 244 - 244
[32] New molecular entities
不详
FORMULARY, 2011, 46 (12) : 507 - 507
[33] New molecular entities
不详
FORMULARY, 2002, 37 (07) : 330 - +
[34] New molecular entities
不详
FORMULARY, 2005, 40 (07) : 210 - 213
[35] New molecular entities
不详
FORMULARY, 2005, 40 (02) : 39 - 39
[36] New molecular entities
不详
FORMULARY, 2010, 45 (02) : 41 - 41
[37] Ibandronate: A potent new bisphosphonate in the management of postmenopausal osteoporosis
Papapoulos, SE
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (05) : 417 - 422
[38] New directions in osteoporosis therapy: Intravenous ibandronate and denosumab
Gim Gee Teng
Nivedita M. Patkar
Kenneth G. Saag
Current Rheumatology Reports, 2007, 9 (1) : 47 - 49
[39] Future directions for new medical entities in osteoporosis
Ferrari, Serge
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 28 (06) : 859 - 870
[40] New formulation with potential for the prevention and treatment of Osteoporosis and Osteoarthritis
Torrent, Anna
Montell, E.
Verges, J.
Ruhi, R.
Dalmau, P.
Carceller, M. C.
Blanco, A.
Terencio, M. C.
Ferrandiz, M. L.
Alcaraz, M. J.
FASEB JOURNAL, 2013, 27

← 1 2 3 4 5 →